Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 112124522 | 11212452 | 2 | F | 20140110 | 20150731 | 20150623 | 20160720 | EXP | US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-038885 | BRISTOL MYERS SQUIBB | 29.00 | YR | F | Y | 0.00000 | 20160720 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 112124522 | 11212452 | 1 | PS | ATAZANAVIR SULFATE | ATAZANAVIR SULFATE | 1 | Oral | 1 DF, QD | 21567 | 1 | DF | QD | |||||||
| 112124522 | 11212452 | 2 | SS | NORVIR | RITONAVIR | 1 | Oral | 1 DF, QD | 0 | 1 | DF | QD | |||||||
| 112124522 | 11212452 | 3 | SS | EMTRICITABINE / TENOFOVIR DISOPROXIL FUMARATE | EMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Oral | 1 DF, QD | 0 | 1 | DF | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 112124522 | 11212452 | 1 | Antiretroviral therapy |
| 112124522 | 11212452 | 2 | Antiretroviral therapy |
| 112124522 | 11212452 | 3 | Antiretroviral therapy |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 112124522 | 11212452 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 112124522 | 11212452 | Abortion spontaneous | |
| 112124522 | 11212452 | Maternal exposure during pregnancy |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |